Dominic Piscitelli - 24 Feb 2026 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
24 Feb 2026
Net transactions value
-$475,966
Form type
4
Filing time
26 Feb 2026, 16:47:24 UTC
Previous filing
06 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Piscitelli Dominic Chief Financial Officer C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO /s/ Christian Kuhlen, attorney-in-fact 26 Feb 2026 0001695028

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Options Exercise $226,720 +52,000 +76% $4.36 120,148 24 Feb 2026 Direct
transaction ORIC Common Stock Sale $702,686 -52,000 -43% $13.51 68,148 24 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Stock Option (right to buy) Options Exercise $0 -52,000 -26% $0.000000 144,500 24 Feb 2026 Common Stock 52,000 $4.36 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.
F2 Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.